Reanalysis of Cost-Effectiveness of Abiraterone Acetate as Second Line Treatment for Metastatic Castration-Resistant Prostate Cancer in Japan Using a Japanese Claim Data Set
Abstract
Authors
H. Shibahara T. Shiroiwa C. Tange K. Nakamura S. Ozono K. Shimozuma